| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2025.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.
| Preliminary, Unaudited Total Sales Results: | ||||||
| 2025 | 2024 | ($ Decrease) $ Increase | (% Decrease) % Increase | |||
| During the Three-Month Periods Ended September 30, | $5.5 million | $6.0 million | ($505,000 | ) | (8 | %) |
| During the Six-Month Periods Ended September 30, | $12.0 million | $11.5 million | $467,000 | 4 | % | |
| During the Nine-Month Periods Ended September 30, | $20.0 million | $18.7 million | $1.3 million | 7 | % | |
| During the Trailing Twelve-Month Periods Ended September 30, | $27.8 million | $23.8 million | $3.9 million | 16 | % | |
Increased sales during the second half of 2024 and the first half of 2025 were attributable, in part, to the rebuilding of inventories of First Defense® by customers and distributors after an unusually prolonged period of backlogs that peaked in early 2024. In its Form 10-Q filing for the quarter ended June 30, 2025, the Company warned of a potential softening of sales during the second half of 2025 due to this re-stocking of distributor inventories, as the Company came off backlog during the first half of 2025. The drop in sales during the third quarter of 2025 compared to the second quarter of 2025 and to the third quarter of 2024 is consistent with that guidance.
Posted In: ICCC
